Finance

Lists
IKT:NASDAQ
Inhibikase Therapeutics Inc
1,91 US$
-1,55%
(-0,030) 1D
8 ოქტ, 09:45:01 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for IKT...
Open
1,94 US$
High
1,94 US$
Low
1,89 US$
Mkt. cap
266,51 მლნ.
Avg. vol.
512,41 ათ.
Volume
2,05 ათ.
52-wk high
2,61 US$
52-wk low
1,33 US$
EPS
-0,44 US$
Beta
0,89
Shares outstanding
139,54 მლნ.
No. of employees
35
Open
1,94 US$
High
1,94 US$
Low
1,89 US$
Mkt. cap
266,51 მლნ.
Avg. vol.
512,41 ათ.
Volume
2,05 ათ.
52-wk high
2,61 US$
52-wk low
1,33 US$
EPS
-0,44 US$
Beta
0,89
Shares outstanding
139,54 მლნ.
No. of employees
35
News stories
From web sources and news partners
About Inhibikase Therapeutics Inc
CEO-
Employees35
Founded2008
Headquartersუილმინგტონი, დელავერის შტატი, ამერიკის შეერთებული შტატები
Sector-
Websiteinhibikase.com
Analyst ratings
Based on 5 analysts giving stock ratings to IKT in the past 3 months
Strong buy
Buy
5
Hold
0
Sell
0
12-month forecast
Based on 5 Wall Street analysts offering 12 month price targets for IKT in the last 3 months.
Highest
Current 1,91 US$
8,00 US$ (+318,85%)
Average
6,40 US$ (+235,08%)
Lowest
5,00 US$ (+161,78%)
Analyst
Recommendation
Action
Price target
Projected
Date
Gaurav Maini
LifeSci Capital
Buy
Maintained
5,00 US$
+161,8%
09/15/2026
Jason McCarthy
Maxim Group
Buy
Maintained
8,00 US$
+318,8%
08/13/2026
Mazahir Alimohamed
Oppenheimer
Buy
Maintained
5,00 US$
+161,8%
08/12/2026
Ram Selvaraju
H.C. Wainwright
Buy
Reiterated
8,00 US$
+318,8%
07/31/2026
Jason Zemansky
Bank of America Securities
Buy
Maintained
6,00 US$
+214,1%
07/27/2026
Olivia Brayer
Cantor Fitzgerald
Buy
Maintained
4,00 US$
+109,4%
05/18/2026
Aydin Huseynov
Ladenburg Thalmann & Co.
Buy
Initiated
4,00 US$
+109,4%
03/04/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
სექ. 2025
დეკ. 2025
მარ. 2026
ივნ. 2026
Revenue
-
-
-
-
Cost of goods sold
7,65 მლნ.
-23,43 მლნ.
-
-
Cost of revenue
7,65 მლნ.
-23,43 მლნ.
-
-
Research and development expenses
-
22,39 მლნ.
10,84 მლნ.
13,39 მლნ.
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
5,61 მლნ.
6,77 მლნ.
7,38 მლნ.
7,66 მლნ.
Operating expense
5,61 მლნ.
29,17 მლნ.
18,22 მლნ.
21,05 მლნ.
Total operating expenses
13,26 მლნ.
5,73 მლნ.
18,22 მლნ.
21,05 მლნ.
Operating income
-13,26 მლნ.
-5,73 მლნ.
-18,22 მლნ.
-21,05 მლნ.
Other non operating income
-
-
1,46 მლნ.
1,46 მლნ.
EBT including unusual items
-11,93 მლნ.
-12,73 მლნ.
-16,38 მლნ.
-19,59 მლნ.
EBT excluding unusual items
-12,42 მლნ.
-4,69 მლნ.
-16,75 მლნ.
-19,59 მლნ.
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-11,93 მლნ.
-12,73 მლნ.
-16,38 მლნ.
-19,59 მლნ.
Net profit margin
-
-
-
-
Earnings per share
-
-
-0,10
-0,11
Interest and investment income
838,09 ათ.
1,04 მლნ.
-
-
Interest expense
-
-
-
-
Net interest expenses
838,09 ათ.
1,04 მლნ.
-
-
Depreciation and amortization charges
-
-
-
-
EBITDA
-13,24 მლნ.
-5,73 მლნ.
-18,20 მლნ.
-21,04 მლნ.
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google აპები